【明報專訊】The government has approved the emergency use of a vaccine developed by BioNTech, a German drugmaker, in Hong Kong. The first batch of about one million doses is expected to arrive in Hong Kong in late February and the vaccination will begin in March at the earliest. When it comes to fighting the pandemic, a two-pronged approach is necessary, and the elimination of the virus in communities and vaccination are of equal importance. One should not be biased in favour of one option or the other. Amid the scarce supply of coronavirus vaccines around the globe, a vaccine that satisfies the threshold of the WHO and the standards set by the Hong Kong government will be worth introducing regardless of the place of production or brand.